Patent US4818752A successfully refreshed from Google Patents.
US4818752A
Expired / Lapsed
US
⏱️ 0.0 years remaining
Soluble phosphorylated glucan: methods and compositions for treatment of neoplastic diseases
Assignee: Bioglucans LP
•
Filing: 1987-02-10
•
Granted: 1989-04-04
•
Expires: 2007-02-10
Abstract
Abstract A new class of soluble phosphorylated glucans is described as well as the process for making the same. According to one embodiment, the soluble phosphorylated glucan is derived from the yeast Saccharomyces cerevisiae. The soluble phosphorylated glucans are useful for prophylactic and therapeutic applications against neoplastic, bacteria, viral, fungal and parasitic diseases. The soluble phosphorylated glucans are used either alone or in combination with a known antimicrobial agent for prophylactic and therapeutic antimicrobial applications. Additionally, they may be administered either alone or as a non-toxic adjuvant, in combination with chemotherapy. The soluble phosphorylated glucans are also useful for stimulating macrophage cells, either in vivo or in vitro, to produce a cytotoxic/cyctostatic factor effective against cancer cells.
Inventors
- 👤 David L. Williams
- 👤 I. William Browder
- 👤 Nicholas R. Diluzio, deceased
Bibliographic Details
Application Number
—
Jurisdiction
US
Data Source
google_patents
Last Synchronized
2026-10-29 09:35
CPC Classifications
A; A61; A61K; A61K31/00; A61K31/70; A61K31/715; C; C08; C08B; C08B37/00; C08B37/0006; C08B37/0024; A61P; A61P31/00; A61P31/04; A61P35/00; A61P37/00; C07; C07H; C07H3/00; C07H3/06; C12; C12P; C12P19/00; C12P19/04
Claims Analysis
Total Claims: 20
Claim 1
Independent Claim
78 words
A pharmaceutical composition for the treatment of a malignant neoplastic disease in animals or humans, comprising a therapeutically effective amount of a soluble glucan which comprises a phosphorylated poly-[beta-(1-3)glucopyranose] chain which is characterized by: (a) the capability of dissolving in water or an aqueous solution; (b) being non-toxic, non-immunogenic and substantially non-pyrogenic; and (c) the capability of exerting a profound immunobiological response when administered in vivo to an animal or to a human, and a physiologically acceptable carrier.
Claim 2
Dependent Claim
78 words
A pharmaceutical composition for the treatment of a malignant neoplastic disease in animals or humans, comprising a therapeutically effective amount of a soluble glucan which comprises a phosphorylated poly-[beta-(1-3)glucopyranose] chain which is characterized by: (a) the capability of dissolving in water or an aqueous solution; (b) being non-toxic, non-immunogenic and substantially non-pyrogenic; and (c) the capability of exerting a profound immunobiological response when administered in vivo to an animal or to a human, and a physiologically acceptable carrier.
Claim 3
Dependent Claim
30 words
The composition according to claim 1, in which the soluble glucan is further characterized by the substantially complete absence of triple helical chains as determined by nuclear magnetic resonance spectroscopy.
Claim 4
Dependent Claim
27 words
The composition according to claim 1, in which the soluble glucan is further characterized by having a degree of phosphorylation ranging from about 1.4% to about 3.4%.
Claim 5
Dependent Claim
27 words
The composition according to claim 1, in which the soluble glucan is further characterized by having a molecular weight ranging from about 10,000 to about 100,000 daltons.
Claim 6
Dependent Claim
27 words
The composition according to claim 1, in which the soluble glucan ss further characterized by having a molecular weight ranging from about 100,000 to about 500,000 daltons.
Claim 7
Dependent Claim
17 words
The composition according to claim 1, in which the soluble glucan is obtained from a microbial source.
Claim 8
Dependent Claim
14 words
The composition according to claim 6, in which the microbial source is Saccahromyces cerevisiae.
Claim 9
Dependent Claim
15 words
The soluble glucan according to claim 6, in which the microbial source is Coriolus versicolor.
Claim 10
Dependent Claim
15 words
The soluble glucan according to claim 6, in which the microbial source is Sclerotium glucanium.
Claim 11
Dependent Claim
11 words
The composition according to claim 1, further comprising an anti-tumor agent.
Claim 12
Dependent Claim
13 words
The composition according to claim 10, in which the anti-tumor agent is cyclophosphamide.
Claim 13
Independent Claim
80 words
A method for treatment of a malignant neoplastic disease in animals and humans, comprising administering to an animal or a human so affected a therapeutically effective amount of a soluble glucan which comprises a phosphorylated poly-[beta-(1-3)glucopyranose] chain which is characterized by: (a) the capability of dissolving in water or an aqueous solution; (b) being non-toxic, non-immunogenic and substantially non-pyrogenic; and (c) the capability of exerting a profound immunobiological response when administered in vivo to an animal or to a human.
Claim 14
Independent Claim
80 words
A method for treatment of a malignant neoplastic disease in animals and humans, comprising administering to an animal or a human so affected a therapeutically effective amount of a soluble glucan which comprises a phosphorylated poly-[beta-(1-3)glucopyranose] chain which is characterized by: (a) the capability of dissolving in water or an aqueous solution; (b) being non-toxic, non-immunogenic and substantially non-pyrogenic; and (c) the capability of exerting a profound immunobiological response when administered in vivo to an animal or to a human.
Claim 15
Dependent Claim
34 words
A method for treatment of a malignant neoplastic disease in animals and humans, comprising administering to an animal or a human so affected a therapeutically effective amount of the copposition according to claim 1.
Claim 16
Dependent Claim
34 words
A method for treatment of a malignant neoplastic disease in animals and humans, comprising administering to an animal or a human so affected a therapeutically effective amount of the composition according to claim 10.
Claim 17
Dependent Claim
13 words
The method according to claim 14, in which the anti-tumor agent is cyclosphosphamide.
Claim 18
Dependent Claim
22 words
The method according to claim 12, in which the soluble phosphorylated glucan is administered topically, intravenously, intraperitoneally, subcutaneously, orally or by inhalation.
Claim 19
Dependent Claim
20 words
The method according to claim 13, in which the composition is administered topically, intravenously, intraperitoneally, subcutaneously, orally or by inhalation.
Claim 20
Dependent Claim
22 words
The method according to claim 14, in which the soluble phosphorylated glucan is administered topically, intravenously, intraperitoneally, subcutaneously, orally, or by inhalation.
References Cited (Backward Citations)
US3081226A
Cited
US3396082A
Cited
US4493894A
Cited
US4138479A
Cited
US4202966A
Cited
US4225673A
Cited
US4237266A
Cited
US4396611A
Cited
US4340673A
Cited
USPTO Annuity & Maintenance Windows
| Annuity Stage | Window Opens | Payment Deadline | Surcharge Period Until | Estimated Fee | Status |
|---|---|---|---|---|---|
| 3.5 Years (Year 4) | 1992-04-03 | 1992-10-03 | 1993-04-04 | $2000.00 | Window Closed / Lapsed |
| 7.5 Years (Year 8) | 1996-04-03 | 1996-10-03 | 1997-04-04 | $3760.00 | Window Closed / Lapsed |
| 11.5 Years (Year 12) | 2000-04-03 | 2000-10-03 | 2001-04-04 | $7700.00 | Window Closed / Lapsed |